Home

Zydus Lifesciences Ltd PE Ratio

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

PE

23.5

Last updated on: Jan 15, 2025

Key Highlights

  • The P/E Ratio of Zydus Lifesciences Ltd is 23.5 as of 15 Jan 9.00 AM .
  • The P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Latest Trading Price of Zydus Lifesciences Ltd is ₹ 1000 as of 14 Jan 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Zydus Lifesciences Ltd

No data available

Company Fundamentals for Zydus Lifesciences Ltd

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

Share Price

₹ 1000.8

26.50 (2.72%)

stock direction

Last updated on: Jan 14, 2025

Market Price of Zydus Lifesciences Ltd

1M

1Y

3Y

5Y

Monitoring Zydus Lifesciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Jan 20251000.8
13 Jan 2025974.3
10 Jan 20251004.05
09 Jan 20251009.4
08 Jan 2025981.55
07 Jan 20251001.2
06 Jan 2025961.75
03 Jan 2025975.55
02 Jan 2025990.55
01 Jan 2025973.65

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

che

Weakness

3

che

Opportunity

0

che

Threats

2

che

BlinkX Score for Zydus Lifesciences Ltd

Asset Value vs Market Value of Zydus Lifesciences Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Zydus Lifesciences Ltd100703
Sun Pharmaceuticals Industries Ltd424382
Divis Laboratories Ltd159224
Cipla Ltd116943
Dr Reddys Laboratories Ltd111588

PE Ratio of Zydus Lifesciences Ltd Explained

``

100703

Market cap

4303

Earnings

23.5X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Zydus Lifesciences Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Zydus Lifesciences Ltd

No data available

* All values are in %

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Zydus Lifesciences Ltd News Hub

Zydus Life gains as Q1 PAT climbs 31% YoY to Rs 1,420 cr

Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quareter ended 3

Read more

2024-08-09 00:00:00

Zydus Lifesciences consolidated net profit rises 30.64% in the June 2024 quarter

Net profit of Zydus Lifesciences rose 30.64% to Rs 1419.90 crore in the quarter ended June 2024 as a

Read more

2024-08-09 00:00:00

Zydus receives USFDA approval for Valbenazine Capsules

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (

Read more

2024-08-09 00:00:00

Zydus Lifesciences Ltd soars 1.83%, rises for third straight session

Zydus Lifesciences Ltd is up for a third straight session in a row. The stock is quoting at Rs 1296.

Read more

2024-08-08 00:00:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Zydus Lifesciences Ltd

What is the current PE Ratio of Zydus Lifesciences Ltd?

The Current PE Ratio of Zydus Lifesciences Ltd is 23.54 as on 15 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 15 Jan 2025.

What was the PE Ratio of Zydus Lifesciences Ltd last year?

The PE Ratio of Zydus Lifesciences Ltd was 25.37 last year, now the PE ratio is 23.54, showing a year-on-year growth of -7.2%.

What does the PE Ratio of Zydus Lifesciences Ltd indicate about its stock?

The PE Ratio of Zydus Lifesciences Ltd is 23.54. This ratio indicates that investors are willing to pay 23.54 times the earnings per share for each share of Zydus Lifesciences Ltd.

What is the PE Ratio Growth of Zydus Lifesciences Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Zydus Lifesciences Ltd grew by -7.2% whereas, the EPS ratio grew by -35.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions